



**RIFAMPICIN, ISONIAZID AND ETHAMBUTOL  
HYDROCHLORIDE TABLETS**  
**Revised draft proposal for *The International Pharmacopoeia***  
**(September 2007)**

***REVISED DRAFT FOR DISCUSSION***

---

© World Health Organization 2007

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations' concerned staff and member organizations) without the permission of WHO. The draft should not be displayed on any web site.

Please send any request for permission to:

Dr Sabine Kopp, Quality Assurance & Safety: Medicines (QSM), Department of Medicines Policy and Standards (PSM), World Health Organization, CH-1211 Geneva 27, Switzerland.

Fax: (41-22) 791 4730; e-mails: [kopps@who.int](mailto:kopps@who.int); [bonnyw@who.int](mailto:bonnyw@who.int)

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this draft is complete and correct and shall not be liable for any damages incurred as a result of its use.

**SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/07.220**

*International Pharmacopoeia monograph on Rifampicin, Isoniazid  
and Ethambutol hydrochloride tablets*

	<b>Date</b>
Preparation of first draft by collaborating laboratory	May 2007
First draft mailed out for comments	June 2007
Any comments received to be reviewed in Consultation on Specifications for Medicines and Quality Control Laboratory Issues	27-29 June 2007
Contact with laboratory concerning specific issues to be resolved	August 2007
Second draft prepared	September 2007
Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations for possible adoption	15-19 October 2007

**RIFAMPICIN, ISONIAZID AND ETHAMBUTOL  
HYDROCHLORIDE TABLETS**  
**Revised draft proposal for *The International Pharmacopoeia***  
**(September 2007)**

**Category.** Antituberculosis drugs.

**Storage.** Rifampicin, Isoniazid and Ethambutol hydrochloride tablets should be kept in a tightly closed container, protected from light.

**Additional information.** Strength in the current WHO Model list of essential medicines: 150 mg Rifampicin, 75 mg Isoniazid and 275 mg Ethambutol hydrochloride. The tablets are coated.

### Requirements

Comply with the monograph for "Tablets".

**Definition.** Rifampicin, Isoniazid and Ethambutol hydrochloride tablets contain Rifampicin, Isoniazid and Ethambutol Hydrochloride. They contain not less than 90.0% and not more than 110.0% of the amounts of rifampicin ( $C_{43}H_{58}N_4O_{12}$ ), isoniazid ( $C_6H_7N_3O$ ) and ethambutol hydrochloride ( $C_{10}H_{24}N_2O_2, 2HCl$ ) stated on the label.

**Manufacture.** The manufacturing process and the product packaging are designed and controlled so as to minimize the moisture content of the tablets. They ensure that, if tested, the tablets would comply with a loss on drying limit of not more than 30 mg/g when determined by drying freshly powdered tablets to constant mass under vacuum at 60°.

### Identity tests

- Either tests A and B or test C may be applied.
- A. See the test described below under Assay method A. The retention times of the two principal peaks in the chromatogram obtained with solution (1) correspond to those of the principal peaks in the chromatogram obtained with solution (2).
- B. See the test described below under Assay method B. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to that of the principal peak in the chromatogram obtained with solution (2).
- C. Carry out test C.1 or, where UV detection is not available, test C.2.
  - C.1 Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 100 volumes of methanol R and 1.5 volumes of strong ammonia solution R as the mobile phase. Apply separately to the plate 5 µl of each of the following two solutions in methanol R. For solution (A) shake a quantity of the

powdered tablets equivalent to about 5 mg Isoniazid for 15 minutes with 5 ml of methanol R, filter, and use the filtrate. For solution (B) use 1 mg isoniazid RS and proportional quantities (according to the ratio in the tablet) of rifampicin RS, and ethambutol hydrochloride RS per ml of methanol R. After removing the plate from the chromatographic chamber, allow it to dry in a current of air, place in a chamber with iodine vapour, and allow to stand for 20 minutes. Examine the chromatogram immediately in ultraviolet light (254 nm).

The principal spots obtained with solution A correspond in position, appearance and intensity to those obtained with solution B.

- C.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, using the conditions described above under test A.1 but using silica gel R5 as the coating substance. After removing the plate from the chromatographic chamber, allow it to dry in a current of air, place in a chamber with iodine vapour, and allow to stand for 20 minutes. Examine the chromatogram immediately in daylight.

The principal spots obtained with solution A correspond in position, appearance and intensity to those obtained with solution B.

**Rifampicin-related substances.** Carry out the test as described under 1.14.4 High-performance liquid chromatography, preparing the solutions and using the conditions given below under Assay method B.

Inject 20 µl each of solutions (1), (3) (4) and (5). The test is not valid unless in the chromatogram obtained with solution (4) the resolution between the peaks is at least 4.

In the chromatograms obtained with solutions (4) and (5) the following impurity peaks are eluted at the following relative retention with reference to rifampicin (retention time about 25 minutes): 3-(isonicotinoylhydrazinomethyl)rifamycin [the "hydrazone" resulting from reaction between 3-formylrifamycin and isoniazid] about 0.5; rifampicin quinone about 0.7.

In the chromatogram obtained with solution (1), the area of any peak corresponding to the hydrazone impurity is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (5.0%), the area of any peak corresponding to rifampicin quinone is not more than 0.8 times the area of the principal peak in the chromatogram obtained with solution (3) (4.0%) and the area of any other peak is not greater than 0.3 times the area of the principal peak in the chromatogram obtained with solution (3) (1.5%). The sum of the areas of all the peaks, other than the principal peak, is not greater than twice the area of the principal peak obtained with solution (3) (10.0% with reference to the content of rifampicin). Disregard any peak with an area less than 0.02 times the area of the principal peak in the chromatogram obtained with solution (3) (0.1%) and any peak with relative retention time less than 0.23 with reference to rifampicin.

*[Note from the Secretariat: As agreed by the WHO Expert Committee on Specifications for Pharmaceutical Preparations for the finalized texts for TB dosage form monographs published on the Medicines web site (QSM/EC/06.13), solution (5) (see under Assay method B) describes the in situ preparation of the hydrazone impurity. The agreed change will be made to the finalized texts before inclusion in the first Supplement to the 4<sup>th</sup> edition.]*

## Assay

### A. *For isoniazid and ethambutol hydrochloride*

Determine by 1.14.4 High-performance liquid chromatography, using a stainless steel column (15 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups, (5 µm)<sup>1</sup>. As the mobile phase, use a solution prepared as follows: dissolve 50 g ammonium acetate R and 0.2 g copper(II) acetate R in 1000 ml of water and adjust to pH 5.0 with glacial acetic acid R. Mix 940 ml of this solution with 60 ml methanol R.

Prepare the following solutions in water. For solution (1) weigh and powder 20 tablets. Transfer a quantity of the powder equivalent to about 100 mg Ethambutol hydrochloride, accurately weighed, to a 500 ml volumetric flask. Dissolve in about 400 ml water by shaking for about 15 minutes. [If foaming occurs, use 400 ml of a 4% solution of methanol R in place of the water.] Dilute to 500 ml with water. Filter a portion of this solution through a 0.45 µm filter, discarding the first few ml of the filtered solution. For solution (2) dissolve 27.3 mg of isoniazid RS and 100 mg ethambutol hydrochloride RS in 500 ml water.

Operate with a flow rate of 2.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 270 nm.

Inject alternately 20 µl each of solutions (1) and (2). (The peak for isoniazid is eluted at a retention time of approximately 1.6 minutes, and that for ethambutol hydrochloride at a retention time of approximately 6 minutes.)

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the content of isoniazid, C<sub>6</sub>H<sub>7</sub>N<sub>3</sub>O and ethambutol hydrochloride, C<sub>10</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>, 2HCl.

### B. *For rifampicin*

Prepare fresh solutions and perform the assay without delay. Low-actinic glassware is recommended.

Determine by 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically bonded octadecylsilyl groups, (5 µm)<sup>1</sup>. As the mobile phase, use a mixture of 6 volumes of methanol R and 4 volumes of phosphate buffer pH 7.0 (potassium dihydrogen phosphate R (0.01 mol/l), adjusted with sodium hydroxide (0.1 mol/l)VS).

Prepare the following solutions in a mixture of 4 volumes of methanol R and 6 volumes of phosphate buffer pH 7.0. For solution (1) weigh and powder 20 tablets. Without delay, shake a quantity of the powder equivalent to about 40 mg Rifampicin in 200 ml and filter. Solution (2) contains 0.20 mg rifampicin RS per ml. For solution (3) dilute a suitable volume of solution (1) to obtain a concentration equivalent to 10 µg Rifampicin per ml. Solution (4) contains 0.2 mg rifampicin RS per ml and 0.2 mg rifampicin quinone RS per ml. For solution (5) dissolve 4 mg of rifampicin RS and 2 mg of isoniazid RS in 25.0 ml of acetic acid (~60g/l) TS and keep the solution at room temperature for 30 minutes.

---

<sup>1</sup> Luna® is suitable.

Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 254 nm.

Inject 20 µl of solution (4). The assay is not valid unless the resolution between the peaks is at least 4.

Inject alternately 20 µl each of solutions (1) and (2). Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2), and calculate the content of rifampicin, C<sub>43</sub>H<sub>58</sub>N<sub>4</sub>O<sub>12</sub> in the tablets.

*[Note from the Secretariat:* The preparation of solutions (1) to (4) has been modified from that described in the finalized texts for TB dosage form monographs published on the Medicines website in order to improve the stability of the test solution. It is intended to make corresponding changes to the finalized texts before inclusion in the first Supplement to the 4<sup>th</sup> edition.]

**Dissolution test.** *To be added for rifampicin.*

\*\*\*

Draft for discussion